NASDAQ:AXGN AxoGen (AXGN) Stock Forecast, Price & News $4.85 -0.14 (-2.81%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$4.63▼$5.0150-Day Range$4.85▼$8.9552-Week Range$4.63▼$13.66Volume575,720 shsAverage Volume231,283 shsMarket Capitalization$208.45 millionP/E RatioN/ADividend YieldN/APrice Target$16.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AxoGen MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside240.2% Upside$16.50 Price TargetShort InterestBearish3.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$188,900 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.63) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector622nd out of 963 stocksElectromedical Equipment Industry14th out of 22 stocks 3.5 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.50, AxoGen has a forecasted upside of 240.2% from its current price of $4.85.Amount of Analyst CoverageAxoGen has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.56% of the float of AxoGen has been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in AxoGen has recently increased by 21.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AXGN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for AxoGen this week, compared to 1 article on an average week.MarketBeat Follows5 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $188,900.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.21% of the stock of AxoGen is held by insiders.Percentage Held by Institutions83.77% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.63) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -8.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -8.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AxoGen (NASDAQ:AXGN) StockAxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Read More AXGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXGN Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comAxoGen (NASDAQ:AXGN) Raised to Buy at StockNews.comSeptember 15, 2023 | americanbankingnews.comStockNews.com Downgrades AxoGen (NASDAQ:AXGN) to HoldSeptember 24, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 5, 2023 | finance.yahoo.comAxogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™August 23, 2023 | msn.comCantor Fitzgerald Reiterates Axogen (AXGN) Overweight RecommendationAugust 21, 2023 | finance.yahoo.comAxogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, OhioAugust 10, 2023 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) Q2 2023 Earnings Call TranscriptAugust 8, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on AxoGen (AXGN)September 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 8, 2023 | finance.yahoo.comAxogen, Inc. Reports 2023 Second Quarter Financial ResultsAugust 8, 2023 | finance.yahoo.comAxoGen (AXGN) Reports Q2 Loss, Lags Revenue EstimatesJuly 27, 2023 | finance.yahoo.comAxogen to Participate at Canaccord Genuity’s 43rd Annual Growth ConferenceJuly 26, 2023 | finance.yahoo.comAxogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023July 5, 2023 | fool.comAxoGen (NASDAQ: AXGN)June 10, 2023 | finance.yahoo.comWith 71% ownership, AxoGen, Inc. (NASDAQ:AXGN) boasts of strong institutional backingJune 9, 2023 | finance.yahoo.comWall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a BetMay 24, 2023 | finance.yahoo.comAxogen to Participate at Jefferies Healthcare ConferenceMay 12, 2023 | finance.yahoo.comAxogen to Participate at JMP Securities Life Sciences ConferenceMay 10, 2023 | msn.comAxoGen GAAP EPS of -$0.10 beats by $0.12, revenue of $36.7M beats by $1.24MMay 10, 2023 | finance.yahoo.comAxogen, Inc. Reports 2023 First Quarter Financial ResultsMay 10, 2023 | msn.comAxoGen Q1 2023 Earnings PreviewApril 18, 2023 | finance.yahoo.comAxogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023April 18, 2023 | finance.yahoo.comEven With A 26% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance CompletelyMarch 17, 2023 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) Q4 2022 Earnings Call TranscriptMarch 16, 2023 | finance.yahoo.comAxoGen Full Year 2022 Earnings: EPS Beats ExpectationsMarch 14, 2023 | finance.yahoo.comAxogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial ResultsMarch 10, 2023 | finance.yahoo.comAxogen, Inc. Appoints Marc Began as Executive Vice President and General CounselSee More Headlines Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address AXGN Company Calendar Last Earnings8/07/2023Today9/24/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXGN CUSIPN/A CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees394Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.50 High Stock Price Forecast$20.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+240.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,950,000.00 Net Margins-15.86% Pretax Margin-15.86% Return on Equity-19.48% Return on Assets-10.02% Debt Debt-to-Equity Ratio0.68 Current Ratio3.60 Quick Ratio2.71 Sales & Book Value Annual Sales$138.58 million Price / Sales1.50 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book2.03Miscellaneous Outstanding Shares42,980,000Free Float39,885,000Market Cap$208.45 million OptionableOptionable Beta0.68 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMs. Karen Zaderej (Age 61)Chairman, Pres & CEO Comp: $852.18kMr. Peter J. Mariani (Age 59)Exec. VP & CFO Comp: $532.5kMr. Michael Donovan (Age 58)VP of Operations Comp: $406.02kMr. Angelo G. Scopelianos Ph.D. (Age 68)Chief R&D Officer Comp: $540.91kEd JoyceDirector of Investor RelationsMr. Marc A. Began (Age 55)Exec. VP, Gen. Counsel & Chief Compliance Officer Ms. Doris QuackenbushVP of SalesMr. Jens Schroeder KempChief Marketing OfficerMs. Maria D. Martinez (Age 55)Chief HR Officer Mr. Erick DeVinney (Age 47)VP of Peripheral Nerve Science and Clinical Innovation More ExecutivesKey CompetitorsEdap TmsNASDAQ:EDAPSemler ScientificNASDAQ:SMLRZynexNASDAQ:ZYXIHyperfineNASDAQ:HYPRPixie Dust TechnologiesNASDAQ:PXDTView All CompetitorsInsiders & InstitutionsAmy Mcbride WendellBought 10,000 shares on 9/6/2023Total: $62,200.00 ($6.22/share)Portside Wealth Group LLCBought 122,808 shares on 9/1/2023Ownership: 0.286%Perceptive Advisors LLCBought 55,031 shares on 8/24/2023Ownership: 3.408%William P Mr. BurkeBought 10,000 shares on 8/23/2023Total: $65,600.00 ($6.56/share)Osaic Holdings Inc.Bought 2,788 shares on 8/21/2023Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions AXGN Stock - Frequently Asked Questions Should I buy or sell AxoGen stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares. View AXGN analyst ratings or view top-rated stocks. What is AxoGen's stock price forecast for 2023? 4 equities research analysts have issued 12 month target prices for AxoGen's shares. Their AXGN share price forecasts range from $15.00 to $20.00. On average, they predict the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 240.2% from the stock's current price. View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts. How have AXGN shares performed in 2023? AxoGen's stock was trading at $9.98 at the beginning of 2023. Since then, AXGN shares have decreased by 51.4% and is now trading at $4.85. View the best growth stocks for 2023 here. Are investors shorting AxoGen? AxoGen saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,410,000 shares, an increase of 21.6% from the August 15th total of 1,160,000 shares. Based on an average trading volume of 275,400 shares, the days-to-cover ratio is currently 5.1 days. Approximately 3.6% of the company's shares are sold short. View AxoGen's Short Interest. When is AxoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our AXGN earnings forecast. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) released its quarterly earnings results on Monday, August, 7th. The medical equipment provider reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07. The medical equipment provider earned $38.16 million during the quarter, compared to analyst estimates of $39.40 million. AxoGen had a negative trailing twelve-month return on equity of 19.48% and a negative net margin of 15.86%. What ETF holds AxoGen's stock ? iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio. What guidance has AxoGen issued on next quarter's earnings? AxoGen updated its FY 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $154.00 million-$159.00 million, compared to the consensus revenue estimate of $157.43 million. What is Karen Zaderej's approval rating as AxoGen's CEO? 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL). What is AxoGen's stock symbol? AxoGen trades on the NASDAQ under the ticker symbol "AXGN." Who are AxoGen's major shareholders? AxoGen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (9.12%), BlackRock Inc. (7.66%), William Blair Investment Management LLC (3.75%), Perceptive Advisors LLC (3.41%), Silvercrest Asset Management Group LLC (2.15%) and State Street Corp (2.14%). Insiders that own company stock include Amy Mcbride Wendell, Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AxoGen's stock price today? One share of AXGN stock can currently be purchased for approximately $4.85. How much money does AxoGen make? AxoGen (NASDAQ:AXGN) has a market capitalization of $208.45 million and generates $138.58 million in revenue each year. The medical equipment provider earns $-28,950,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. How many employees does AxoGen have? The company employs 394 workers across the globe. How can I contact AxoGen? AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801. This page (NASDAQ:AXGN) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.